Monday, December 04, 2023 10:48:05 PM
WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the Company will host a virtual key opinion leader (KOL) event on Monday, December 11, at 8:00 a.m. ET to discuss highlights from its poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. Following the prepared remarks, the call will be opened for a live question and answer session. To submit a question, please reach out to questions@lifesciadvisors.com.
The event will provide an in-depth review of the presentation related to lead TCR-T cell therapy candidates, TSC-100 and TSC-101, designed to target HA-1 and HA-2, respectively, to treat residual disease and prevent relapse in patients with acute myeloid leukemia, acute lymphocytic leukemia or myelodysplastic syndromes undergoing allogeneic haploidentical hematopoietic cell transplantation with reduced intensity conditioning. (NCT05473910)
Featured speakers include:
Monzr M. Al Malki, M.D., Associate Professor in the Department of Hematology & Hematopoietic Cell Transplantation and Director of the Unrelated Donor Bone Marrow Transplant and Haploidentical Transplant Programs at City of Hope
Gavin MacBeath, Ph.D., Chief Executive Officer, TScan Therapeutics
Debora Barton, M.D., Chief Medical Officer, TScan Therapeutics
Shrikanta Chattopadhyay, M.D., M.M.Sc., Senior Vice President of Medical and Translational Medicine, TScan Therapeutics
Registration for the live event can be found here. A replay will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com.
Recent TCRX News
- TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:34 PM
- TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares • GlobeNewswire Inc. • 04/24/2024 03:03:30 PM
- TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting • GlobeNewswire Inc. • 04/22/2024 09:01:23 PM
- TScan Therapeutics Announces Closing of Upsized Public Offering • GlobeNewswire Inc. • 04/19/2024 02:05:23 PM
- TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering • GlobeNewswire Inc. • 04/17/2024 04:30:57 AM
- TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering • GlobeNewswire Inc. • 04/16/2024 08:25:22 PM
- TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities • GlobeNewswire Inc. • 04/16/2024 08:01:00 PM
- TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/06/2024 09:11:41 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:05:39 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 12:30:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 12:15:10 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:45:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 12:15:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 12:15:01 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 12:15:08 PM
- TScan Gets FDA Clearance of Investigational New Drug Application for Cancer Treatment • Dow Jones News • 08/29/2023 12:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 11:30:55 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 11:15:53 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2023 11:39:09 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2023 11:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/29/2023 12:30:28 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM